Literature DB >> 10073699

Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study.

L Kjellberg, Z Wang, F Wiklund, K Edlund, T Angstr M, P Lenner, I Sj Berg, G Hallmans, K L Wallin, M Sapp, J Schiller, G Wadell, C G M Hlck, J Dillner.   

Abstract

Sexual history is an established risk determinant for cervical neoplasia. It is not clear if human papillomavirus (HPV) exposure entirely explains the sexual behaviour-related risk or if other sexually transmitted agents may act as cofactors for HPV in carcinogenesis. The aim of this study was to elucidate whether HPV exposure or HPV persistence explains the sexual history-related risk of high-grade cervical intraepithelial neoplasia (CIN) using a population-based case-control study of most of the 254 women referred to colposcopy in the Vasterbotten county in Sweden because of an abnormal cervical smear during October 1993 to December 1995 and 320 age-matched women from the general population. The women were interviewed for sexual history and tested for presence of serum antibodies to HPV-16, -18 and -33 as well as for presence of HPV DNA in cervical brush samples. HPV-16, -18 and -33 seropositivity was specific for the corresponding type of HPV DNA, dependent on the lifetime sexual history and associated with a two- to threefold increased risk of CIN 3. There was no sexual history-related risk of CIN among HPV-seropositive women and adjustment for HPV DNA presence explained the sexual history-related risk of CIN. In conclusion, HPV exposure appeared to explain the sexual history-related risk of high-grade CIN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073699     DOI: 10.1099/0022-1317-80-2-391

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples.

Authors:  J H Nelson; G A Hawkins; K Edlund; M Evander; L Kjellberg; G Wadell; J Dillner; T Gerasimova; A L Coker; L Pirisi; D Petereit; P F Lambert
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix.

Authors:  Karin Sundström; Sandra Eloranta; Pär Sparén; Lisen Arnheim Dahlström; Anthony Gunnell; Anders Lindgren; Juni Palmgren; Alexander Ploner; Carani B Sanjeevi; Mads Melbye; Joakim Dillner; Hans-Olov Adami; Nathalie Ylitalo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-29       Impact factor: 4.254

Review 4.  Oral Sex and HPV: Population Based Indications.

Authors:  Anupam Mishra; Veerendra Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-02-29

5.  Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

Authors:  A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

7.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

Review 8.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

9.  Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.

Authors:  Proscovia B Namujju; Lea Hedman; Klaus Hedman; Cecily Banura; Edward K Mbidde; Dennison Kizito; Romano N Byaruhanga; Moses Muwanga; Reinhard Kirnbauer; Heljä-Marja Surcel; Matti Lehtinen
Journal:  BMC Res Notes       Date:  2011-06-06

10.  Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.

Authors:  Ruanne V Barnabas; Päivi Laukkanen; Pentti Koskela; Osmo Kontula; Matti Lehtinen; Geoff P Garnett
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.